Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;1(9):145-55.
doi: 10.1186/1939-4551-1-9-145.

H1 antihistamines: current status and future directions

F Estelle R Simons  1 , Keith J Simons
Affiliations

H1 antihistamines: current status and future directions

F Estelle R Simons et al. World Allergy Organ J. 2008 Sep.

Abstract

In this review, we compare and contrast the clinical pharmacology, efficacy, and safety of first-generation H1 antihistamines and second-generation H1 antihistamines. First-generation H1 antihistamines cross the blood-brain barrier, and in usual doses, they potentially cause sedation and impair cognitive function and psychomotor performance. These medications, some of which have been in use for more than 6 decades, have never been optimally investigated. Second-generation H1 antihistamines such as cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine cross the blood-brain barrier to a significantly smaller extent than their predecessors. The clinical pharmacology, efficacy, and safety of these medications have been extensively studied. They are therefore the H1 antihistamines of choice in the treatment of allergic rhinitis, allergic conjunctivitis, and urticaria. In the future, clinically advantageous H1 antihistamines developed with the aid of molecular techniques might be available.

PubMed Disclaimer

References

    1. Akdis CA, Simons FER. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006;1:69–76. doi: 10.1016/j.ejphar.2005.12.044. - DOI - PubMed
    1. Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004;1:2203–2217. doi: 10.1056/NEJMra033121. - DOI - PubMed
    1. Simons FER, Akdis CA. In: Middleton's allergy principles and practice. 7. Adkinson NF Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Lemanske RF, Simons FER, editor. St Louis, MO: Mosby, Inc, [an affiliate of Elsevier Science]; 2008. Histamine and antihistamines; pp. 1517–1547.
    1. Holgate ST, Canonica GW, Simons FER, Taglialatela M, Tharp M, Timmerman H, Yanai K. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003;1:1305–1324. doi: 10.1046/j.1365-2222.2003.01769.x. - DOI - PubMed
    1. Simons FER. In: Histamine and H1-antihistamines in allergic disease. 2. Simons FER, editor. New York, NY: Marcel Dekker, Inc; 2002. H1-antihistamines in children; pp. 437–464.